SGLT2 Inhibitors in Diabetes:

SGLT2 inhibitors (Sodium-Glucose Cotransporter-2 inhibitors) are a class of medications that have revolutionized the treatment of Type 2 Diabetes. These drugs work by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This helps lower blood sugar levels independently of insulin. In addition to improving glycemic control, SGLT2 inhibitors have been shown to provide cardiovascular and renal benefits, reducing the risk of heart failure, kidney disease, and diabetic complications. Recent studies have also highlighted their potential role in weight loss and blood pressure reduction. Given these multiple benefits, SGLT2 inhibitors are increasingly recommended for patients with Type 2 Diabetes, especially those with coexisting cardiovascular or kidney conditions.

    SGLT2 Inhibitors in Diabetes: Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in